MAZE vs TECH · $525.3M cap vs P/E 65, rev $1.22B
Maze Therapeutics, Inc. Common Stock (MAZE) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Maze Therapeutics, Inc. Common Stock (MAZE) is a biotechnology company listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported MAZE revenue for 2025-06-30 was $0. Net income was -$66.5M. Revenue was down 100.0% from 2024-09-30 to 2025-06-30. MAZE currently screens at market cap $525.3M.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
MAZE currently screens at market cap $525.3M. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the MAZE and TECH stock pages for the full models.
Not investment advice.